The effects of @entity11545 treatment on caregiver time in XXXX .

@entity1 @entity11545 @entity3457 @entity195
AIM: The aim of the study was to determine whether the clinical benefits of @entity11545 for @entity1 with @entity195 lead to benefits for caregivers. METHODS: Data were pooled from two concurrent, multi-centre, randomized, double-blind, placebo-controlled, 6-month trials. Time caregivers spent assisting with @entity3457 ( @entity3457 ) and time @entity1 could be left unsupervised each day were assessed using the Allocation of Caregiver Time Survey. In total, 825 @entity1 with mild-to-moderate @entity195 were included. RESULTS: At endpoint, caregivers of @entity11545 -treated @entity1 were more likely to report reductions (41% vs 37%), maintenance (19% vs 14%) or smaller increases (26% vs 34% reporting an increase >30 minutes) in time assisting with @entity3457 compared with the placebo group (p=0.026; Wilcoxon rank-sum test). The mean daily time difference was 32 minutes (p=0.011). Among @entity1 with moderate @entity195 , caregivers of @entity11545 -treated @entity1 were even more likely to report reductions (46% vs 37%), maintenance (15% vs 6%) or smaller increases (25% vs 42% for increases >30 min) vs placebo (p=0.004), with a mean daily time saving of 53 minutes (p=0.021). Caregivers of @entity11545 -treated @entity1 were more likely to report increases (22% vs 18%), maintenance (45% vs 43%) or smaller reductions (30% vs 37% for reductions >30 minutes) in time the @entity1 could be left unsupervised compared with placebo (p=0.027). Mean daily time saving was 27 minutes. Among @entity1 with moderate @entity195 , the treatment effect was greater (p=0.029), with caregivers in the @entity11545 group reporting the change in time left unsupervised as 68 minutes longer each day than caregivers of @entity1 receiving placebo. CONCLUSION: The clinical benefits of @entity11545 for @entity1 with @entity195 are also associated with benefits to caregiving.
